Core D: Neuroimaging Core

神经影像学核心摘要 由Adam Brickman博士和布拉德克里斯蒂安博士领导的ABC-DS神经影像核心将采用最先进的 正电子发射断层扫描（PET）和磁共振成像（MRI）神经成像技术， 根据目前的研究，定量唐氏综合征（DS）中的淀粉样蛋白、tau蛋白和神经变性（AT（N）） 阿尔茨海默病（AD）的病理生理学模型以及相关的脑血管，微结构， 和功能性生物标志物。神经影像学核心的具体目标是：（1）监督协调的 在8个临床性能研究中心中的每一个采集PET和MRI数据;（2）定量主要结局 （3）将处理后的神经成像数据整合到ABC-DS中， 数据库，以支持拟议的项目;和（4）提供策划的主要成果变量和原始 神经影像学的数据，以更广泛的科学界。总体扫描协议将遵循制定的协议 由阿尔茨海默病神经成像倡议（ADNI）用于MRI（结构和功能）和PET（淀粉样蛋白， tau，FDG）。结果变量由特定于模态的分析节点导出，并对每种模态进行分析 由一个在神经成像生物标志物方面有专业知识的实验室进行。核心将利用NIA赞助的 目前支持正在进行的大规模AD神经成像计划的资源（例如ADNI，主要是 遗传性阿尔茨海默病网络（DIAN）），以提供一个充分开发的数据访问管道，鼓励科学 DS中神经影像学生物标志物的研究。

Neuroimaging Core Abstract The ABC-DS Neuroimaging Core, led by Drs. Adam Brickman and Brad Christian, will apply state-of-the art positron emission tomography (PET) and magnetic resonance imaging (MRI) neuroimaging techniques to quantitate amyloid, tau, and neurodegeneration (AT(N)) in Down syndrome (DS) according to current pathophysiological models of Alzheimer’s disease (AD) together with related cerebrovascular, microstructural, and functional biomarkers. The specific aims of the Neuroimaging Core are to: (1) oversee the harmonized acquisition of PET and MRI data at each of the 8 clinical performance sites; (2) quantitate primary outcome measures for each neuroimaging modality; (3) integrate the processed neuroimaging data into a ABC-DS database to support the proposed projects; and (4) provide curated primary outcome variables and raw neuroimaging data to the wider scientific community. The overall scanning protocols will follow those developed by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) for MRI (structural and functional) and PET (amyloid, tau, FDG). The outcome variables are derived by modality-specific analytic nodes, with each modality analyzed by a single laboratory with expertise in that neuroimaging biomarker. The Core will utilize NIA-sponsored resources that currently support ongoing large-scale AD neuroimaging initiatives (e.g. ADNI, Dominantly Inherited Alzheimer Network (DIAN)) to provide a fully developed data-access pipeline that encourages scientific investigation of neuroimaging biomarkers in DS.